Biotechnology

Galmed Pharma

Galmed Pharmaceuticals Grants New Use Patent for ARAMCHOL in Combination with Madrigal Pharmaceuticals' REZDIFFRA

Galmed Pharma released FY2025 Q3 earnings on November 26 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.3464 (forecast USD -0.54)

Galmed Pharma released FY2025 9 Months Earnings on November 26 Post-Market (EST), Actual Revenue USD 0, Actual EPS USD -1.5987

Galmed Pharmaceuticals Annual General Meeting Proposals Passed

Galmed Pharma released FY2025 Q2 earnings on August 28 (EST), actual revenue USD 0, actual EPS USD -0.6319 (forecast EPS USD -0.83)

Galmed Pharma released FY2025 Semi-Annual Earnings on August 28 (EST), actual revenue USD 0, actual EPS USD -1.2554

Galmed Pharmaceuticals Ltd. Approves $10 Million Cash Reserve for Digital Asset Purchases

Galmed Pharma released FY2025 Q1 earnings on May 22 (EST), actual revenue USD 0, actual EPS USD -0.6203 (forecast EPS USD -0.89)

Galmed Pharmaceuticals Announces Narrowed Q1 2025 Net Loss

Galmed Reports Promising Preclinical Results for Aramchol in Treating PSC

Galmed Pharmaceuticals and Entomus Collaborate to Develop Novel Semaglutide Sublingual Formulation

Galmed Pharmaceuticals Launches VCU Project to Address Drug Resistance in Gastrointestinal Cancer

Galmed Pharmaceuticals (GLMD) Reports Positive Results from Phase 1 Bioavailability Study of Aramchol Meglumine

Maxim Group Downgrades Galmed Pharmaceuticals Rating to Hold, Stock Price Drops 5.5%

Galmed Pharma released FY2024 Q4 earnings on April 2, 2025 (EST) with actual revenue of 0 USD and EPS of -1.9968 USD

Galmed Pharma released FY2024 annual earnings on April 2, 2025 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -8.0756 USD (forecast -15.48 USD)

Galmed Pharma released FY2024 Q3 earnings on November 14 (EST) with actual revenue of 0 USD and EPS of -2.3074 USD

Galmed Pharma released FY2024 9 Months Earnings on November 14 (EST), with actual revenue of USD 0 and EPS of USD -6.5364

Galmed Pharmaceuticals Regains Compliance with Minimum Bid Price Requirement

Galmed Pharma released FY2024 Q2 earnings on August 28 (EST), actual revenue USD 0, actual EPS USD -1.6507

Rich Sparkle

Novabay Pharmac

Valens Semiconductor

Greenpower Motor

Alpha Tech

Offerpad Solutions

VCI Global

Tryhard

Tradr 2X Long APLD Daily ETF

ZeZentalis Pharma

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap

Galmed Pharma(GLMD.US)